Abstract: The present invention relates to compounds having activity at both the human glucosedependent insulinotropic polypeptide (GIF) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus ("T2DM"). Also, the compounds may be useful in the treatment of obesity.
Description:AS FILED PDF DOCUMENTS , Claims:AS FILED PDF DOCUMENTS
| # | Name | Date |
|---|---|---|
| 1 | 202418103660-STATEMENT OF UNDERTAKING (FORM 3) [27-12-2024(online)].pdf | 2024-12-27 |
| 2 | 202418103660-Sequence Listing in txt [27-12-2024(online)].txt | 2024-12-27 |
| 3 | 202418103660-Sequence Listing in PDF [27-12-2024(online)].pdf | 2024-12-27 |
| 4 | 202418103660-POWER OF AUTHORITY [27-12-2024(online)].pdf | 2024-12-27 |
| 5 | 202418103660-FORM-26 [27-12-2024(online)].pdf | 2024-12-27 |
| 6 | 202418103660-FORM 18 [27-12-2024(online)].pdf | 2024-12-27 |
| 7 | 202418103660-FORM 1 [27-12-2024(online)].pdf | 2024-12-27 |
| 8 | 202418103660-DECLARATION OF INVENTORSHIP (FORM 5) [27-12-2024(online)].pdf | 2024-12-27 |
| 9 | 202418103660-COMPLETE SPECIFICATION [27-12-2024(online)].pdf | 2024-12-27 |
| 10 | 202418103660-Proof of Right [31-12-2024(online)].pdf | 2024-12-31 |
| 11 | 202418103660-FORM 3 [13-06-2025(online)].pdf | 2025-06-13 |